Travere Therapeutics (TVTX) Profit After Tax (2011 - 2026)

Travere Therapeutics has reported Profit After Tax for 16 years, with the latest figure at -$37.1 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 10.0% year-over-year to -$37.1 million; the trailing twelve-month figure through Mar 2026 stood at -$46.1 million (up 79.64% YoY), and the FY2025 full-year result was -$50.3 million, up 84.32% from the prior year.
• Profit After Tax for Q1 2026 stood at -$37.1 million, down from -$22.0 million in the prior quarter.
• The five-year high for Profit After Tax was $150.7 million in Q3 2023, with the low at -$136.1 million in Q1 2024.
• Historically, Profit After Tax has averaged -$50.3 million across 5 years, with a median of -$67.0 million in 2022.
• Annual changes were most pronounced in 2023 — Profit After Tax soared 279.31% — and 2024, when it plunged 136.32%.
• Travere Therapeutics' Profit After Tax stood at -$85.6 million in 2022, then retreated by 5.3% to -$90.2 million in 2023, then jumped by 33.16% to -$60.3 million in 2024, then surged by 63.52% to -$22.0 million in 2025, then plunged by 68.75% to -$37.1 million in 2026.
• The last three Profit After Tax figures came in at -$37.1 million (Q1 2026), -$22.0 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.